Dianthus Therapeutics

What Dianthus Therapeutics does

Dianthus Therapeutics is a clinical-stage biotechnology company developing next-generation complement and bifunctional therapeutics for severe autoimmune diseases. The company was launched in 2019 with a $100 million Series A and became publicly traded on Nasdaq (ticker: DNTH) in September 2023 following a reverse merger with Magenta Therapeutics. It operates co-headquartered in Waltham, MA and New York, NY, with 51–100 employees, and has raised more than $1.6 billion in cumulative capital across multiple private and public financings, ending Q1 2026 with approximately $1.2 billion in cash and an operating runway extending into 2030.

Dianthus's pipeline is anchored by two clinical-stage candidates built on the proprietary YTE half-life extension platform, which enables subcutaneous self-administration as infrequently as once every four weeks. Claseprubart (DNTH103) is a monoclonal antibody with high selectivity for only the active C1s complement protein, in Phase 3 development for CIDP (positive early GO decision, 75% responder rate), with prior Phase 2 data in generalized myasthenia gravis and a planned program in multifocal motor neuropathy; FDA Orphan Drug Designation has been granted in gMG. DNTH212 is a first-in-class bifunctional fusion protein co-developed with Nanjing Leads Biolabs under a deal valued at up to $1 billion; it simultaneously suppresses Type 1 interferon (via BDCA2) and modulates B cell function (via BAFF/APRIL) and entered Phase 1 in December 2025 for rheumatology indications including Sjögren's, systemic lupus erythematosus, and dermatomyositis.

The business model is pre-commercial: Dianthus generates only nominal revenue ($280 thousand in Q3 2025) from incidental collaboration and licensing activities. Future revenue will derive from US and global commercialization of claseprubart and DNTH212 through specialty pharmacy distribution channels typical of rare-disease biologics, targeting combined US patient populations exceeding 150,000 across gMG, CIDP, and MMN. The company maintains an enterprise field-sales posture with active participation in major healthcare investor conferences (Jefferies, Goldman Sachs, Guggenheim, TD Cowen) and is building commercial readiness through specialty pharma channel planning and senior commercial hires.

Name

Dianthus Therapeutics

Legal name

Dianthus Therapeutics, Inc.

Website

https://dianthustx.com

Company type

Public

Founded year

2023

Operating status

Operating

Headcount range

101–250 employees

Short description

Dianthus Therapeutics is a clinical-stage biotechnology company developing next-generation YTE-enabled antibody therapeutics — claseprubart (anti-C1s) and DNTH212 (BDCA2/BAFF-APRIL bifunctional) — for severe autoimmune neuromuscular and rheumatology diseases, targeting 150,000+ US patients across gMG, CIDP, MMN, Sjögren's, SLE, and dermatomyositis.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

akta.pro secondary industries

Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB), Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

Keywords

• Complement therapeutics
• Monoclonal antibody therapy
• Autoimmune disease drugs
• Biopharmaceutical development
• Rare disease biologics

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Biopharmaceutical Development and Commercialization: Dianthus Therapeutics is a clinical-stage biotechnology company that does not yet have commercialized products. The company generates minimal revenue from licensing arrangements and collaboration activities. The primary revenue model will be based on commercialization of investigational drugs upon regulatory approval, focusing on specialty pharmaceuticals for rare and severe autoimmune diseases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Dianthus Therapeutics is a clinical-stage biotechnology company developing next-generation antibody therapeutics for severe autoimmune diseases. Its lead candidate, claseprubart (DNTH103), is a monoclonal antibody engineered with YTE half-life extension that selectively inhibits only the active C1s complement protein for neuromuscular disorders such as generalized Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy. Its second candidate, DNTH212, is a first-in-class bifunctional fusion protein that suppresses Type 1 interferon via BDCA2 and modulates B cells via BAFF/APRIL inhibition for rheumatology indications including Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis.

Product overview

Dianthus Therapeutics is a clinical-stage biotechnology company developing two distinct therapeutic candidates for severe autoimmune diseases. Its lead product, claseprubart (DNTH103), is a monoclonal antibody targeting the C1s complement protein for neuromuscular disorders including generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN). The second candidate, DNTH212, is a bifunctional fusion protein targeting Type 1 interferon suppression and B cell modulation for rheumatology indications including Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis. Both candidates utilize YTE half-life extension technology for subcutaneous self-administration.

Differentiator

Problem solved

Functional benefit

Products and services

• Claseprubart (DNTH103) A purposefully engineered, extended half-life monoclonal antibody that selectively inhibits only the active C1s complement protein driving classical complement pathway-driven disease pathology. Designed for self-administered subcutaneous injections as infrequently as once every four weeks and indicated for neuromuscular autoimmune disorders including generalized Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy.
• DNTH212 (LBL-047) A first-in-class, extended half-life bifunctional fusion protein that simultaneously targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production and inhibits BAFF/APRIL to suppress B cell function, addressing both innate and adaptive immune mechanisms. Being developed for rheumatology autoimmune indications including Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis.

Quantifiable outcome

• 75% responder rate in Phase 3 CAPTIVATE trial for CIDP in first 40 patients treated with claseprubart up to 13 weeks
• +4 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Nanjing Leads Biolabs Co., Ltd.coreStrategic or Co-development Partner · 1 December 2025Global partnership with Nanjing Leads Biolabs Co., Ltd. for DNTH212 (LBL-047) development. Dianthus secured exclusive global rights outside Greater China for the bifunctional fusion protein targeting autoimmune diseases. The partnership is valued at up to $1 billion. Leads Biolabs is developing LBL-047 in China while Dianthus advances global development. Phase 1 trial initiated in December 2025 in China and other locations with healthy volunteers and SLE patients.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Argenx: Argenx develops Vyvgart (efgartigimod), an FcRn inhibitor approved for generalized myasthenia gravis (gMG) and expanding into CIDP and other autoimmune indications. Direct competitor to Dianthus in the gMG/CIDP autoimmune space with overlapping target patient populations.
• UCB: UCB markets Rystiggo (rozanolixizumab, FcRn inhibitor) for gMG and is developing zilucoplan (C5 inhibitor) for CIDP and gMG. A direct competitor in the neuromuscular autoimmune market where claseprubart is positioned, with established commercial infrastructure.
• Alexion (AstraZeneca): Alexion's Soliris and Ultomiris (C5 complement inhibitors) are approved for gMG and PNH, establishing the complement inhibitor category. Direct competitor to claseprubart in complement-driven autoimmune diseases, with deep rare disease commercial capabilities.
• Immunovant: Immunovant is developing FcRn inhibitors (batoclimab, IMVT-1402) for autoimmune indications including gMG, CIDP, and Graves' disease. Direct competitor in the autoimmune neurology space with similar clinical development focus as Dianthus.
• Aurinia Pharmaceuticals: Aurinia developed and commercialized voclosporin (Lupkynis) for lupus nephritis, an autoimmune therapy. Comparable clinical-stage-to-commercial biotech in autoimmune disease space; several Dianthus leaders (Dr. Randhawa, Rivka Gluck, Sue Evans) came from Aurinia, indicating operational similarity.

Broad incumbents

• Takeda Pharmaceutical: Takeda is a global pharmaceutical company with a major rare disease and plasma-derived therapies franchise (including Takhzyro for hereditary angioedema, a complement-related condition). Broad incumbent in autoimmune and complement-mediated diseases, with global commercial reach exceeding Dianthus's future specialty focus.
• BioMarin Pharmaceutical: BioMarin is an established rare disease biotech with multiple approved enzyme replacement and gene therapies. Comparable business model of developing high-priced biologics for small rare disease populations, with deeper commercial experience than Dianthus.
• Alnylam Pharmaceuticals: Alnylam pioneered RNAi therapeutics with multiple approved rare disease products (Onpattro, Givlaari, Oxlumo). Comparable specialty biotech developing novel platform-based therapies for rare diseases, with established global commercialization.
• Vertex Pharmaceuticals: Vertex is a large biotech with rare disease franchises (cystic fibrosis, sickle cell) and an emerging autoimmune program. While broader in scope, it represents a comparable high-revenue-per-patient rare disease biologics business model.

Emerging players

• Cabaletta Bio: Cabaletta Bio is a clinical-stage biotech developing cell therapies for autoimmune diseases including myositis, SLE, and pemphigus. Comparable clinical-stage autoimmune company with a different modality (CAR-T) but overlapping target indications with DNTH212's rheumatology focus.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights8 records

Customer concentration

• LinkedInlinkedin.com/company/dianthus-therapeutics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds6 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dianthus Therapeutics